Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Steroids, stress, and body mass index interact to accelerate female pubertal development.

The Journal of clinical endocrinology and metabolism·2026
Same author

A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study).

BMC medical ethics·2026
Same author

Personalized Decision-Making in Risk-Reducing Surgery of the Ovaries.

JAMA network open·2026
Same author

Pulsed Low-Dose-Rate Chemoradiation Induces Stromal Reprogramming in Pancreatic CAF-Generated ECM: Quantification by the HOST-Factor.

Gastro hep advances·2026
Same author

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal·2026
Same author

The ENGAGE study: a randomized trial optimizing uptake of germline cancer genetic services in childhood cancer survivors.

Lancet regional health. Americas·2026

相关实验视频

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

技术与痴呆症 会议前会议

Angela R Bradbury1, Brian L Egleston2, Elisabeth Wood1

  • 1University of Pennsylvania, Philadelphia, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括
此摘要是机器生成的。

通过电话或视频会议披露Apolipoprotein E (APOE) 基因型结果显示,在遗传知识和痛苦方面,结果相似. 视频会议可能为某些子组,特别是非白人参与者,在管理焦虑和感知风险方面提供轻微的好处.

更多相关视频

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

相关实验视频

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

科学领域:

  • 遗传学 遗传学 是一个
  • 神经科学是一个神经科学.
  • 临床试验 临床试验

背景情况:

  • 在阿尔茨海默氏症预防试验和指导抗粉样蛋白治疗决策方面,APOE基因型定型至关重要.
  • 携带APOE4的人面临更高的治疗副作用风险,需要明确的通信协议.
  • 分享APOE结果的基于证据的实践是必要的,以支持临床决策.

研究的目的:

  • 为了比较APOE4基因型结果的电话披露 (TD) 与视频会议披露 (VD) 的有效性.
  • 评估患者报告的结果 (PROs),包括遗传知识,疾病特异性痛苦和满意度.
  • 根据APOE基因型和参与者人口统计数据来评估结果的潜在差异.

主要方法:

  • 一个多中心随机试验 (CONNECT4) 涉及60-75岁的认知正常成年人.
  • 参与者被随机分配,通过TD或VD与遗传顾问一起接受APOE4披露.
  • 在披露后的多个时间点收集了PRO;T测试和费舍尔的精确测试用于比较.

主要成果:

  • 在TD和VD手臂之间没有观察到遗传知识或痛苦的显著差异.
  • 总体而言,对TD的满意度略高.
  • 亚组分析显示,同位素和非携带者之间感知风险的差异,以及非白人参与者与VD减少状态焦虑.

结论:

  • 无论是TD还是VD都是向认知不受损的个人披露APOE结果的可行方法.
  • 视频会议可能为某些子组提供特定的优势,包括非白人参与者的潜在焦虑减轻.
  • 这些发现支持基于个体需求和偏好的基因咨询和结果披露的灵活方法.